mRNA: A promising platform for cancer immunotherapy

Byoungjae Kong; Yelee Kim; Eun Hye Kim; Jung Soo Suk; Yoosoo Yang

doi:10.1016/j.addr.2023.114993

mRNA: A promising platform for cancer immunotherapy

Byoungjae Kong
, Yelee Kim
, Eun Hye Kim
, Jung Soo Suk
, Yoosoo Yang

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Messenger RNA (mRNA) is now in the limelight as a powerful tool for treating various human diseases, especially malignant tumors, thanks to the remarkable clinical outcomes of mRNA vaccines using lipid nanoparticle technology during the COVID-19 pandemic. Recent promising preclinical and clinical results that epitomize the advancement in mRNA and nanoformulation-based delivery technologies have highlighted the tremendous potential of mRNA in cancer immunotherapy. mRNAs can be harnessed for cancer immunotherapy in forms of various therapeutic modalities, including cancer vaccines, adoptive T-cell therapies, therapeutic antibodies, and immunomodulatory proteins. This review provides a comprehensive overview of the current state and prospects of mRNA-based therapeutics, including numerous delivery and therapeutic strategies.

Original language	English (US)
Article number	114993
Journal	Advanced Drug Delivery Reviews
Volume	199
DOIs	https://doi.org/10.1016/j.addr.2023.114993
State	Published - Aug 2023

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.1016/j.addr.2023.114993

Cite this

@article{5fc7d69bf1be468d96b6e9b738fd86e7,

title = "mRNA: A promising platform for cancer immunotherapy",

abstract = "Messenger RNA (mRNA) is now in the limelight as a powerful tool for treating various human diseases, especially malignant tumors, thanks to the remarkable clinical outcomes of mRNA vaccines using lipid nanoparticle technology during the COVID-19 pandemic. Recent promising preclinical and clinical results that epitomize the advancement in mRNA and nanoformulation-based delivery technologies have highlighted the tremendous potential of mRNA in cancer immunotherapy. mRNAs can be harnessed for cancer immunotherapy in forms of various therapeutic modalities, including cancer vaccines, adoptive T-cell therapies, therapeutic antibodies, and immunomodulatory proteins. This review provides a comprehensive overview of the current state and prospects of mRNA-based therapeutics, including numerous delivery and therapeutic strategies.",

author = "Byoungjae Kong and Yelee Kim and Kim, \{Eun Hye\} and Suk, \{Jung Soo\} and Yoosoo Yang",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = aug,

doi = "10.1016/j.addr.2023.114993",

language = "English (US)",

volume = "199",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - mRNA

T2 - A promising platform for cancer immunotherapy

AU - Kong, Byoungjae

AU - Kim, Yelee

AU - Kim, Eun Hye

AU - Suk, Jung Soo

AU - Yang, Yoosoo

PY - 2023/8

Y1 - 2023/8

N2 - Messenger RNA (mRNA) is now in the limelight as a powerful tool for treating various human diseases, especially malignant tumors, thanks to the remarkable clinical outcomes of mRNA vaccines using lipid nanoparticle technology during the COVID-19 pandemic. Recent promising preclinical and clinical results that epitomize the advancement in mRNA and nanoformulation-based delivery technologies have highlighted the tremendous potential of mRNA in cancer immunotherapy. mRNAs can be harnessed for cancer immunotherapy in forms of various therapeutic modalities, including cancer vaccines, adoptive T-cell therapies, therapeutic antibodies, and immunomodulatory proteins. This review provides a comprehensive overview of the current state and prospects of mRNA-based therapeutics, including numerous delivery and therapeutic strategies.

AB - Messenger RNA (mRNA) is now in the limelight as a powerful tool for treating various human diseases, especially malignant tumors, thanks to the remarkable clinical outcomes of mRNA vaccines using lipid nanoparticle technology during the COVID-19 pandemic. Recent promising preclinical and clinical results that epitomize the advancement in mRNA and nanoformulation-based delivery technologies have highlighted the tremendous potential of mRNA in cancer immunotherapy. mRNAs can be harnessed for cancer immunotherapy in forms of various therapeutic modalities, including cancer vaccines, adoptive T-cell therapies, therapeutic antibodies, and immunomodulatory proteins. This review provides a comprehensive overview of the current state and prospects of mRNA-based therapeutics, including numerous delivery and therapeutic strategies.

UR - https://www.scopus.com/pages/publications/85165172077

UR - https://www.scopus.com/pages/publications/85165172077#tab=citedBy

U2 - 10.1016/j.addr.2023.114993

DO - 10.1016/j.addr.2023.114993

M3 - Review article

C2 - 37414361

AN - SCOPUS:85165172077

SN - 0169-409X

VL - 199

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

M1 - 114993

ER -

mRNA: A promising platform for cancer immunotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this